Latest News
Lytix reports phase II results showing durable responses in advanced melanoma
21 April 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) on Tuesday reported final Phase II results for ruxotemitide (LTX-315) in combination with pembrolizumab in patients with PD-1/PD-L1 refractory advanced me...
Rznomics reports RZ-001 interim clinical data in hepatocellular carcinoma at AACR 2026
21 April 2026 - Rznomics Inc, a clinical-stage biopharmaceutical company based in South Korea, announced on Monday the presentation of interim clinical data from its ongoing study of RZ-001, an RNA editing-based investigational anticancer therapy, in...
Atrium Therapeutics announces inducement grants to seven new employees
21 April 2026 - Ribonucleic acid (RNA) therapeutics developer Atrium Therapeutics Inc (Nasdaq:RNA) announced on Monday the award of inducement grants under its 2026 Employment Inducement Incentive Award Plan as a material inducement to the employment...
Akeso presents positive Phase II results from cadonilimab combination study at AACR 2026
21 April 2026 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Monday that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemoth...
LENZ Therapeutics advances VIZZ regulatory expansion with UK submission for presbyopia treatment
20 April 2026 - US pharmaceutical company LENZ Therapeutics Inc (Nasdaq:LENZ) announced on Monday that it has submitted a marketing authorisation application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA...